Q3 2024 EPS Estimates for Cipher Pharmaceuticals Inc. (TSE:CPH) Increased by Analyst

Cipher Pharmaceuticals Inc. (TSE:CPH) (NASDAQ:CPHR) – Equities research analysts at Stifel Canada boosted their Q3 2024 earnings per share (EPS) estimates for shares of Cipher Pharmaceuticals in a note issued to investors on Tuesday, September 24th. Stifel Canada analyst J. Keywood now expects that the company will earn $0.27 per share for the quarter, up from their previous forecast of $0.25. Stifel Canada has a “Strong-Buy” rating on the stock. The consensus estimate for Cipher Pharmaceuticals’ current full-year earnings is $1.42 per share. Stifel Canada also issued estimates for Cipher Pharmaceuticals’ FY2024 earnings at $0.93 EPS.

Cipher Pharmaceuticals (TSE:CPH) (NASDAQ:CPHR) last issued its earnings results on Thursday, August 8th. The company reported C$0.16 EPS for the quarter, topping the consensus estimate of C$0.15 by C$0.01. Cipher Pharmaceuticals had a return on equity of 28.43% and a net margin of 102.01%. The firm had revenue of C$7.26 million during the quarter, compared to analysts’ expectations of C$7.52 million.

Several other research analysts have also issued reports on CPH. Leede Financial lowered shares of Cipher Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Friday, September 13th. Stifel Nicolaus upped their price objective on Cipher Pharmaceuticals from C$16.00 to C$17.00 and gave the company a “buy” rating in a research note on Wednesday.

Cipher Pharmaceuticals Trading Up 9.4 %

Shares of CPH stock opened at C$14.53 on Thursday. The company has a debt-to-equity ratio of 0.33, a quick ratio of 2.67 and a current ratio of 11.18. The firm has a fifty day moving average of C$14.55 and a 200-day moving average of C$10.66. Cipher Pharmaceuticals has a 52-week low of C$4.10 and a 52-week high of C$19.69. The stock has a market cap of C$371.82 million, a price-to-earnings ratio of 11.81 and a beta of 1.25.

About Cipher Pharmaceuticals

Cipher Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada. It offers Epuris (isotretinoin), an oral retinoid indicated for the treatment of severe nodular and/or inflammatory acne, acne conglobate, and recalcitrant acne; Actikerall, a topical solution indicated for the treatment of slightly palpable and/or moderately thick hyperkeratotic actinic keratosis (Grade I/II) of the face, forehead, and balding scalp; Ozanex for the topical treatment of impetigo; Vaniqa, a topical cream for the slowing of the growth of unwanted facial hair in women; Durela, an opioid analgesic for the management of moderate to moderately severe pain in adults; Brinavess for the rapid conversion of onset atrial fibriallation to sinus rhythm in adults; and Aggrastat, a reversible GP IIb/IIIa inhibitor for use in patients with Acute Coronary Syndrome.